Innovacell Advances ICEF15 Phase III Trial Enrollment, Ends Patient Recruitment in Japan and Europe

TOKYO, Aug 06 (Pulse News Wire) – Innovacell (504A.T) reported progress in the international Phase III trial enrollment for ICEF15, targeting fecal incontinence. As of July 29, 271 patients had been enrolled, with projections reaching approximately 285 by mid-August due to faster-than-expected recruitment in Japan and Europe.

The company plans to complete patient enrollment globally by the end of 2026, focusing on adding U.S. participants while concluding new recruitments in Japan and Europe by the end of July. Innovacell's strategy involves maintaining statistical validity without exceeding the planned target of 290 cases, which accounts for potential dropouts during the trial. The company expects to leverage a supplementary enrollment mechanism to ensure sufficient data for efficacy and safety evaluations, potentially surpassing the initial goal but avoiding additional regulatory burdens.

Completion of global enrollment remains scheduled for December 2026. ICEF15 utilizes autologous cell therapy aimed at repairing and regenerating muscle tissue to treat urgent urinary incontinence. With nearly half of incontinence sufferers experiencing urgent symptoms, Innovacell’s pipeline represents a significant advancement in addressing this condition through regenerative medicine. Founded in Japan in 2021 as a spin-off from Austria’s Innsbruck Medical University, Innovacell continues to develop treatments for various forms of incontinence, solidifying its position in the field of cellular therapies.